216 related articles for article (PubMed ID: 28534261)
1. The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes.
Mikov M; Đanić M; Pavlović N; Stanimirov B; Goločorbin-Kon S; Stankov K; Al-Salami H
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):881-890. PubMed ID: 28534261
[TBL] [Abstract][Full Text] [Related]
2. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
4. Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018.
Steinbronn C; Yang X; Yu J; Dimova H; Huang SM; Ragueneau-Majlessi I; Isoherranen N
Clin Pharmacol Ther; 2021 Aug; 110(2):452-463. PubMed ID: 33835478
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
Singh SS
Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
[TBL] [Abstract][Full Text] [Related]
6. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z
Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830
[TBL] [Abstract][Full Text] [Related]
7. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
VandenBrink BM; Isoherranen N
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate.
Rehman SU; Choi MS; Kim IS; Luo Z; Xue Y; Yao G; Zhang Y; Yoo HH
Molecules; 2016 Jun; 21(6):. PubMed ID: 27322236
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
Nettleton DO; Einolf HJ
Curr Top Med Chem; 2011; 11(4):382-403. PubMed ID: 21320066
[TBL] [Abstract][Full Text] [Related]
10. Human hepatic cell cultures: in vitro and in vivo drug metabolism.
Gómez-Lechón MJ; Donato T; Ponsoda X; Castell JV
Altern Lab Anim; 2003; 31(3):257-65. PubMed ID: 15612868
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
12. Computational prediction of cytochrome P450 inhibition and induction.
Kato H
Drug Metab Pharmacokinet; 2020 Feb; 35(1):30-44. PubMed ID: 31902468
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
Riley RJ; Wilson CE
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
[TBL] [Abstract][Full Text] [Related]
14. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
Tornio A; Filppula AM; Backman JT
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():48-59. PubMed ID: 34410044
[TBL] [Abstract][Full Text] [Related]
15. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
Bachmann KA; Lewis JD
Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
[TBL] [Abstract][Full Text] [Related]
16. Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data.
Zhao YS; Chen F; Li L
Curr Drug Metab; 2014; 15(8):767-90. PubMed ID: 25705906
[TBL] [Abstract][Full Text] [Related]
17. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
Iga K
J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
[TBL] [Abstract][Full Text] [Related]
18. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.
Isoherranen N; Hachad H; Yeung CK; Levy RH
Chem Res Toxicol; 2009 Feb; 22(2):294-8. PubMed ID: 19216580
[TBL] [Abstract][Full Text] [Related]
19. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Derungs A; Donzelli M; Berger B; Noppen C; Krähenbühl S; Haschke M
Clin Pharmacokinet; 2016 Jan; 55(1):79-91. PubMed ID: 26123704
[TBL] [Abstract][Full Text] [Related]
20. Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes.
Hameed PN; Verspoor K; Kusljic S; Halgamuge S
BMC Bioinformatics; 2017 Mar; 18(1):140. PubMed ID: 28249566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
